Thank you to all our members who participated in our recent survey on treatment. CIPO used the data collected to create a patient submission to the CADTH (Canadian Agency on Drugs and Technology in Heath) for a new product that is currently being reviewed. You can read CIPO’s submission on the product, Hyqvia, here
Now that CIPO, and other groups, have made our submissions to CADTH the submissions will be reviewed and CADTH, who will make their initial recommendation in November. After CADTH’s initial recommendation, there will be time for feedback from stakeholders and expert committees and then it will go to the provinces and territories, who will make a final recommendation on whether or not it should be made available to patients, whether or not it should have restrictions to use, and on which formulary(ies) it should be carried.
Again, thank you for taking part in the start of this process. The patient voice is crucial as we advocate for treatment options and alternatives for immunodeficiency patients in Canada.